Verification: 472acb06bbb2f6379ffcdd5ef9b6d310
Home » Blog » Mankind Pharma’s reduces price of heart failure drug, NEPTAZ by 70 per cent

Mankind Pharma’s reduces price of heart failure drug, NEPTAZ by 70 per cent

Mankind Pharma’s heart failure drug, NEPTAZ, [which is manufactured using US FDA approved DMF grade API], now at a 70 percent Lesser Price

In order to make quality drugs affordable and accessible to all Indian patients, Mankind Pharma which [manufactures] [NEPTAZ using US FDA-approved DMF grade API] has announced a price reduction of up to 70% across different SKUs for its brand NEPTAZ (Sacubitril/Valsartan). This price reduction is expected to make NEPTAZ affordable to Indian patients. Mankind [launched NEPTAZ in the year 2022] pursuant to a [collaboration agreement] with [Novartis.]

NEPTAZ contains a [complex, comprised of Sacubitril and Valsartan, in a specific molar ratio. Both these medicines work in a synergistic way to reduce hospitalisation as well as mortality in patients with chronic heart failure. [The product belongs to a class of medicines called Angiotensin Receptor Neprilysin Inhibitors (ARNI) which is approved by Regulatory authorities across the globe including US and Europe.] [As per varied statistics, heart Failure claims more than 17.9 million lives every year globally whilst, medicines for critically ill heart patients are usually expensive.]

The price reduction by 70% of NEPTAZ, manufactured using US FDA-approved DMF grade API, meeting global standards will make the drug affordable and accessible to all patients suffering from heart failure conditions in India.

Leave a Reply

Your email address will not be published. Required fields are marked *